Core Insights - Guangkang Biochemical (300804.SZ) reported a total operating revenue of 399 million yuan for the first half of 2025, an increase of 81.18 million yuan compared to the same period last year, representing a year-on-year growth of 25.55% [1] - The net profit attributable to shareholders was 29.01 million yuan, up by 7.05 million yuan from the same period last year, reflecting a year-on-year increase of 32.13% [1] - The net cash inflow from operating activities was 38.67 million yuan, an increase of 39.09 million yuan compared to the same period last year [1] Financial Metrics - The latest gross profit margin is 23.63%, an increase of 0.22 percentage points from the previous quarter and up by 0.88 percentage points year-on-year [2] - The latest return on equity (ROE) is 2.14%, an increase of 0.46 percentage points compared to the same period last year [2] - The diluted earnings per share (EPS) is 0.39 yuan, an increase of 0.09 yuan year-on-year, representing a growth of 31.18% [2] - The total asset turnover ratio is 0.19 times, an increase of 0.03 times year-on-year, reflecting a growth of 15.08% [2] - The inventory turnover ratio is 1.82 times, an increase of 0.40 times compared to the same period last year, representing a year-on-year growth of 28.46% [2] Shareholder Information - The number of shareholders is 10,800, with the top ten shareholders holding a total of 52.54 million shares, accounting for 71.00% of the total share capital [2] - The largest shareholder is Cai Danqun, holding 34.8% of the shares [2] Debt Metrics - The latest debt-to-asset ratio is 35.92% [3]
广康生化(300804.SZ)：2025年中报净利润为2901.39万元、较去年同期上涨32.13%